Product Details
Product Name:
Tesaglitazar |
CAS No.:
251565-85-2 |
Purity:
99.89% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | Tesaglitazar |
Description | Tesaglitazar is a potent and selective peroxide PPARα / γ receptor dual agonist with a more potent affinity for PPARγ than PPARα, The EC50 values for rat PPARα and human PPARα were 13.4 μM and 3.6 μM, respectively, and 0.2 μM for rat PPARγ and human PPARγ. Tesaglitazar induced DNA synthesis and fibrosarcoma formation in rat subcutaneous mesenchymal cells. |
In vivo | The aim of the present study was to determine whether tesaglitazar attenuates NAFLD and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient (LDLr(-/-)) mice. Tesaglitazar therapeutic group (n=15, 20 μg/kg/day oral treatment for 6 weeks). Tesaglitazar decreased serum glucose and lipid levels compared with the diabetic mice and significantly reduced atherosclerotic lesions, lipid accumulation in the liver, macrophage infiltration, and decreased total hepatic cholesterol and triglyceride content compared to the diabetic mice. In addition, tesaglitazar reduced inflammatory markers at both the serum and mRNA levels. Tesaglitazar may be effective in preventing NAFLD and atherosclerosis in a pre-existing diabetic condition by regulating glucose and lipid metabolism, and the inflammatory response.[1] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 180.0 mg/mL (440.7 mM), Sonication and heating to 60℃ are recommended.
|
Keywords | Tesaglitazar |
Inhibitors Related | PHYTOL | Daidzein | Gemfibrozil | Fenofibrate | Pioglitazone hydrochloride | 5-Aminosalicylic Acid | Naringenin | Fisetin | 2,3-Butanediol | Icariin |
Related Compound Libraries | Nuclear Receptor Compound Library | DNA Damage & Repair Compound Library | Bioactive Compound Library | Anti-Obesity Compound Library | Drug Repurposing Compound Library | Mitochondria-Targeted Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:303760-60-3
$64.00 / 5mg
-
CAS:1032350-13-2
$30.00 / 2mg
-
CAS:27313-86-6
$75.00 / 1mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$1.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2019-08-01 |